Argus analyst Jasper Hellweg lowered the firm’s price target on Incyte to $70 from $80 and keeps a Buy rating on the shares ahead of its Q1 results next week. Shares have fallen 17% over the past three months and underperformed over the past year relative to the S&P500, but the firm remains positive on the company as it advances its pipeline, the analyst tells investors in a research note. Incyte could launch several other blockbuster drugs over the next few years as it has multiple late-stage product candidates under development, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target lowered to $84 from $92 at Oppenheimer
- Piper likes Incyte’s Escient acquisition, looking for more deals
- Roblox upgraded, Qualcomm initiated: Wall Street’s top analyst calls
- Incyte to acquire Escient Pharmaceuticals for $750M
- Incyte initiated with a Neutral at Cantor on ‘lukewarm view’ of pipeline